Top Industry Leaders in the Erythromelalgia Treatment Market
Latest Erythromelalgia Treatment Companies Update:
Teva Pharmaceutical Industries Ltd: In June 2023, Teva announced the launch of Qutenza (capsaicin 8%) patch, the first FDA-approved treatment specifically for Erythromelalgia. This is a significant development offering a dedicated option for managing the burning pain and other symptoms.
Xenon Pharmaceuticals Inc.: In May 2023, Xenon initiated a Phase 3 clinical trial to evaluate the efficacy and safety of its investigational drug XEN401 for the treatment of Erythromelalgia. This trial could potentially lead to another targeted therapy option for patients.
Biogen: In April 2023, Biogen presented encouraging data from a Phase 2 clinical trial for its anti-CGRP antibody BIIB059 as a potential treatment for Erythromelalgia. CGRP (calcitonin gene-related peptide) plays a role in pain signaling, and targeting this pathway could offer a novel approach to managing Erythromelalgia pain.
List of Erythromelalgia Treatment Key companies in the market
-
Teva Pharmaceutical Industries Ltd
-
Xenon
-
Biogen
-
ICAGEN, INC
-
Pfizer Inc
-
Zydus Cadila
-
ANI Pharmaceuticals, Inc
-
Novel Laboratories Inc
-
Norvartis AG
-
Amneal Pharmaceuticals LLC
-
ALLERGAN
-
Bausch Health
-
Akorn, Incorporated
-
INDOCO REMEDIES LTD
-
Somerset Therapeutics, LLC
-
Galderma Laboratories
-
L.P.
-
Acorda Therapeutics, Inc